Loading...
01/11 03:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerns: increasing expenses and net loss, a postponed BLA submission, and vague management responses in the Q&A. Despite potential partnerships and strategic plans, the financial health and uncertainties around funding and timelines overshadow positive aspects. The increase in research and development expenses and the net loss, coupled with the postponed BLA submission, contribute to a negative outlook. The lack of clear guidance and specific plans to expedite regulatory processes further dampens sentiment, leading to a prediction of a negative stock price movement.
Revenues for the 9 months ended September 30, 2025 $0.8 million, a decrease of $1.0 million or 53% year-over-year. The decline was primarily due to decreased participant demand for the Bahamas Registry Trial and reduced demand for contract manufacturing services from a third-party client.
Clinical trial revenue $0.7 million, a decrease of $0.3 million or 36% year-over-year. This was attributed to decreased participant demand for the Bahamas Registry Trial.
Contract manufacturing revenue $0.2 million, a decrease of $0.6 million or 76% year-over-year. The decline was driven by reduced demand for contract manufacturing services from a third-party client.
General and administrative expenses $9.1 million, an increase of $1.7 million or 22% year-over-year. The increase was primarily related to higher personnel and related costs, including severance and equity-based compensation.
Research and development expenses $9.3 million, an increase of $3.2 million or 52% year-over-year. The rise was driven by a $1.8 million increase in personnel and related costs, a $1.2 million increase in supplies and costs associated with technology transfer, and a $0.2 million increase in amortization expense related to patent costs.
Net loss $17.3 million, an increase of $5.4 million or 45% year-over-year. This was due to higher general and administrative expenses and research and development costs.
Cash and cash equivalents as of September 30, 2025 $9.2 million. The company extended its cash runway into late Q1 2026 through disciplined capital allocation and operational decisions.
Laromestrocel: Progress in three programs addressing rare pediatric cardiovascular indications (HLHS and pediatric dilated cardiomyopathy) and chronic age-related indications (Alzheimer's disease and aging-related frailty).
ELPIS II Phase IIb study: Completed enrollment in June for HLHS, with results expected in Q3 2026. This is the largest placebo-controlled study in this rare disease population.
HLHS Program: Potential regulatory approval and commercialization pending ELPIS II results. The program addresses a significant unmet medical need with a large market opportunity.
Alzheimer's Disease Program: Positive Phase IIa results and alignment with FDA on pivotal Phase II/III trial design. Potential for partnerships to advance commercialization.
Financial Management: Extended cash runway into late Q1 2026 through disciplined spending. Exploring additional financing options, including grants and strategic collaborations.
Manufacturing Strategy: Shifted to third-party CMO for commercial manufacturing. Initiated technology transfer and proof-of-concept runs, with plans for larger-scale campaigns.
BLA Preparedness: Focused on HLHS BLA readiness, with structured spending to optimize delivery of ELPIS II results. Full BLA filing expected in 2027.
Partnership Opportunities: Evaluating partnerships across all indications, including HLHS and Alzheimer's, to support development and commercialization.
Financial Stability: The company acknowledges risks in its current financial situation, with cash runway extended only into late Q1 2026. Future financing opportunities are not guaranteed, and failure to secure additional funding could materially impact operations and delay strategic objectives.
Revenue Decline: Revenues for the first nine months of 2025 decreased by 53% compared to 2024, driven by reduced demand for the Bahamas Registry Trial and contract manufacturing services. This decline could impact the company's ability to fund its operations and strategic initiatives.
Increased Expenses: General and administrative expenses increased by 22%, and research and development expenses rose by 52% compared to the same period in 2024. These rising costs contribute to a higher net loss, which increased by 45% year-over-year.
Regulatory and Development Risks: The company faces challenges in meeting regulatory and manufacturing milestones for its BLA submission for HLHS, now delayed to 2027. Any further delays or failures in clinical trials could jeopardize the approval and commercialization timeline.
Market and Competitive Risks: The company operates in a highly competitive and capital-intensive field of stem cell therapy. Failure to demonstrate the efficacy and safety of its therapies in pivotal trials could impact its market position and ability to attract partners or investors.
Operational Risks: The company is transitioning to third-party commercial manufacturing, which introduces risks related to technology transfer, process validation, and reliance on external partners. Any issues in these areas could delay production and regulatory approvals.
HLHS Program: The company is focused on delivering clinical trial results from ELPIS II, a pivotal Phase IIb study in HLHS, with results expected in Q3 2026. Pending positive results, there is a clear path to potential regulatory approval and commercialization.
Financial Resources: The company is actively seeking additional financing through capital raises, grants, and strategic collaborations to support its development programs. Current cash runway extends into late Q1 2026, with plans to utilize an at-the-market financing facility if needed.
BLA Preparedness: The company is preparing for a Biologics License Application (BLA) submission for HLHS in 2027, contingent on successful ELPIS II trial results. Spending has been structured to deliver critical milestones while extending the cash runway.
Alzheimer's Disease Program: The company is exploring collaborations and partnerships for advancing laromestrocel in Alzheimer's disease, following positive Phase IIa results and alignment with the FDA on a pivotal Phase II/III trial design.
Manufacturing Readiness: The company has initiated technology transfer activities with a third-party CMO for commercial manufacturing. Larger-scale manufacturing campaigns are planned to support future commercial production.
The selected topic was not discussed during the call.
The earnings call reveals several concerns: increasing expenses and net loss, a postponed BLA submission, and vague management responses in the Q&A. Despite potential partnerships and strategic plans, the financial health and uncertainties around funding and timelines overshadow positive aspects. The increase in research and development expenses and the net loss, coupled with the postponed BLA submission, contribute to a negative outlook. The lack of clear guidance and specific plans to expedite regulatory processes further dampens sentiment, leading to a prediction of a negative stock price movement.
The earnings call summary indicates a decrease in revenue and increased expenses, leading to a higher net loss. The Q&A section reveals uncertainties in pricing strategies and potential market risks. Although there are positive regulatory milestones and strategic initiatives, the financial challenges and lack of clear guidance on pricing strategies suggest a negative sentiment. Additionally, the public offering and the need for further funding introduce concerns about financial health. Overall, these factors contribute to a negative outlook for the stock price over the next two weeks.
The earnings call presents a mixed picture: strong revenue growth in 2024 and reduced net loss, but Q1 2025 shows declining revenue and increased losses. The company's strategic priorities, such as the HLHS program and Alzheimer's initiatives, are promising, but financial and market demand risks are concerning. The Q&A section reveals some uncertainties, especially regarding patient enrollment and manufacturing scale-up. The absence of a shareholder return plan or guidance adjustments adds to the neutral sentiment. Overall, the stock is likely to remain stable, with no strong catalysts for significant movement.
Despite some positive aspects like the HLHS program's progress and potential market opportunity, the earnings call highlights several concerns. Financially, there's a decline in revenue and increased expenses leading to a higher net loss, raising financial stability issues. The need for additional funding and manufacturing challenges further add to the negative sentiment. The Q&A session reveals uncertainties in market adoption and unclear management responses, exacerbating investor concerns. These factors, coupled with a lack of positive catalysts like partnerships or optimistic guidance, suggest a negative stock price reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
